Wolverine Trading’s Rigel Pharmaceuticals RIGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-1,060
Closed -$28K 6283
2021
Q4
$28K Buy
+1,060
New +$32K ﹤0.01% 5463
2021
Q3
Sell
-2,770
Closed -$123K 6827
2021
Q2
$123K Buy
2,770
+360
+15% +$13.6K ﹤0.01% 5300
2021
Q1
$82K Buy
2,410
+270
+13% +$10.7K ﹤0.01% 5510
2020
Q4
$77K Buy
2,140
+20
+0.9% +$579 ﹤0.01% 4532
2020
Q3
$49K Buy
2,120
+970
+84% +$23.8K ﹤0.01% 4278
2020
Q2
$21K Buy
+1,150
New +$20.7K ﹤0.01% 4435
2019
Q1
Sell
-3,730
Closed -$84K 5170
2018
Q4
$84K Buy
3,730
+190
+5% +$5.36K ﹤0.01% 4035
2018
Q3
$114K Buy
3,540
+2,050
+138% +$61.5K ﹤0.01% 4493
2018
Q2
$53K Hold
1,490
﹤0.01% 4896
2018
Q1
$53K Buy
1,490
+240
+19% +$9.61K ﹤0.01% 4896
2017
Q4
$49K Buy
1,250
+220
+21% +$8.37K ﹤0.01% 4607
2017
Q3
$26K Buy
+1,030
New +$25.1K ﹤0.01% 4296
2016
Q4
Sell
-3,800
Closed -$136K 5006
2016
Q3
$136K Buy
3,800
+740
+24% +$21.2K ﹤0.01% 4055
2016
Q2
$66K Buy
+3,060
New +$76.1K ﹤0.01% 3760

Other funds holding RIGL

Wolverine Trading's RIGL Position: Q2 2024 in Review

Wolverine Trading sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 1,276 shares — an estimated $13.4K sold.

Wolverine Trading first reported a position in RIGL in Q2 2016 and held it in 10 quarters. The position peaked at $125K in Q3 2016. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

  • Wolverine Trading reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Wolverine Trading sold 1,276 Rigel Pharmaceuticals shares in Q2 2024, an estimated $13.4K.
  • Wolverine Trading first reported a position in Rigel Pharmaceuticals in Q2 2016 and held it in 10 quarters.
  • Wolverine Trading's Rigel Pharmaceuticals position peaked at $125K in Q3 2016.
  • 91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Wolverine Trading's 13F filing for Q2 2024, filed 14 Aug 2024.